The objective of this study was to evaluate the knowledge level and perception of dengue fever management among Peruvian physicians and to determine the factors associated with higher knowledge.We conducted an analytical cross-sectional study based on an online survey. To evaluate the factors associated with a high level of knowledge ($70% of correct answers), we used crude (cPR) and adjusted (aPR) prevalence ratios by the Poisson regression model. Of 359 respondents (median age: 33 years; male: 56.5%), 78.8% achieved a high level of knowledge. Multivariable analysis showed an independent association with having read the Peruvian clinical practice guidelines for dengue management (aPR: 1.29; 95% CI: 1.12–1.49), having experience in treating patients (aPR: 1.32; 95% CI: 1.03–1.68), and having treated cases frequently (aPR: 1.22; 95% CI: 1.02–1.46). Residing in the eastern macroregio...

Due to the recent increase of dengue cases in Latin America, preventive measures beyond vector control or community participation are needed. In this regard, the use of vaccines has emerged as a promising tool. To date, there are three vaccines in phase III clinical trials: CYD-TDV, TAK-003 and Butantan-DV, all showing high efficacy and safety. Several Latin American countries have started implementing vaccination programs with TAK-003 (Qgenda®) vaccine since 2023. Brazil has initiated vaccination programs in children aged 10-14 years and Argentina has implemented TAK-003 vaccine in the private sector. In Peru, despite recent outbreaks of dengue, vaccination has not been considered in the national dengue plan. Although its incorporation represents a public health challenge, we believe that the vaccine would be useful in limiting severe cases and mortality from this disease.

Latin America has reported a 9% increase in new HIV infections from 2010 to 2023. Pre-exposure prophylaxis (PrEP) is a crucial biomedical intervention for preventing HIV transmission. Currently, several antiretroviral drugs, in various forms of administration, have demonstrated high efficacy and effectiveness to protect against HIV. Among the oral drugs, we have emtricitabine/te-nofovir and emtricitabine/tenofovir alafenamide, while alternative options include the dapivirine vaginal ring, injectable drugs such as Cabotegravir, and the most recently studied Lenacapavir. Despite their high efficacy and effectiveness, implementing PrEP in Latin America has been challenging throughout the region. Although some countries such as Brazil, Mexico, and Colombia have shown progress in increasing the number of users, there is a significant gap between these countries and others where PrEP access re...